Strategic Initiative

Slingshot members are tracking this corporate initiative:

Rigel Pharmaceuticals ($RIGL) Enters Collaboration and License Agreement with Kissei Pharmaceutical ($KIS.F) to Develop and Commercialize TAVALISSE (fostamatinib disodium hexahydrate) in Japan and other Asian Countries

Source Link:: https://ir.rigel.com/news-releases/news-release-details/rigel-pharmaceuticals-enters-collaboration-and-license-agreement

Do you think this event is important to the companies below? How will it affect their stock price?

Related Companies

Importance

High

Medium

Low

Impact on Stocks

KIS.F

100%

RIGL

100%

SIGN ME UP
I want to vote! LOG ME IN
Now!

Slingshot Insights Explained

JOIN FOR FREE TODAY

Strategic Initiative Date

Announcement Date:

Oct 29, 2018

Projected Implementation:

Q4, 2018

Relevance Tracked Until:

Q1, 2019

Related Projects

Don’t see a project related to the strategic initiative you care about?

Related Keywords Tavalisse, Fostamatinib Disodium Hexahydrate